Dec 24 (Reuters) - Shares of Agios Pharmaceuticals (AGIO) jumped 18% on Wednesday after the U.S. Food and Drug Administration approved the expanded use of its drug for the treatment of a type of blood disorder.
The drug mitapivat is now approved as a treatment for patients with anemia in both non-transfusion-dependent and transfusion-dependent alpha- or beta-thalassemia, the company said late on Tuesday.
Thalassemia is an inherited blood disorder affecting the body's ability to produce hemoglobin and healthy red blood cells.
The drug, under the brand name Aqvesme, is expected to be available in late January next year, following the implementation of the required safety program.
Mitapivat was already approved by the U.S. FDA in 2022 to treat low red blood cell counts in adults with pyruvate kinase deficiency, under the brand name of Pyrukynd.
"The approval unlocks an additional $320 million in peak revenue opportunity layered atop the existing mitapivat franchise," Truist analyst Gregory Renza said.
The latest approval is based on a late-stage study in which patients receiving mitapivat showed a statistically significant increase in hemoglobin response compared to those on placebo.
Aqvesme will carry a boxed warning for liver function tests every four weeks during the first 24 weeks of treatment and advises against use in patients with cirrhosis, Renza added.
(Reporting by Siddhi Mahatole in Bengaluru; Editing by Vijay Kishore)
LATEST POSTS
- 1
When fake data is a good thing – how synthetic data trains AI to solve real problems - 2Cuba says 33 have died of mosquito-borne illnesses as epidemic rages
- 3Why doing good also makes us feel good, during the holidays and beyond
- 4Exploring the Mind boggling Universe of Connections: Individual Bits of knowledge
- 56 Hints to Upgrade Your Appeal, In addition to Your Outlook
- 2025 Yachting Editors' Choice Awards: Yachts
- The Best 20 Photography Instagram Records to Follow
- Dave Coulier shares new cancer diagnosis 1 year after revealing previous diagnosis
- From Modesty to Administration: Self-improvement in Interactive abilities
- Bavarian leader questions Germany's Eurovision participation
- Poland identifies two Ukrainian suspects in railway sabotage blast
- Manual for Picking Coastline Travel
- Manageable Living: Eco-Accommodating Decisions for Regular day to day existence
- Holden Commodore Turbo BT1 Police Interceptor Offered for Sale in Australia
